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Hans D. Ochs,1 Alexandra H. Filipovich,2 Paul Veys,3 Morton J. Cowan,4 Neena Kapoor5Wiskott-Aldrich syndrome (WAS) is a rare X-linked immunodeficiency disorder that has a variable clinical
phenotype that correlates with the type of mutation in WASP, the gene encoding the WAS protein
(WASP).WASP is a key regulator of actin polymerization in hematopoietic cells and has well-defined domains
that are involved in signaling, cell locomotion, and immune synapse formation. Classic WAS often results
from mutations that cause the absence of WASP expression, associated with thrombocytopenia with small
platelets, sinopulmonary infections, and eczema in young males. Other phenotypes associated with expres-
sion of mutated WASP are X-linked thrombocytopenia and neutropenia. To date, the only curative therapy
forWAS is hematopoietic cell transplantation (HCT) although gene therapy forWAS is under study. At least
2 retrospective studies of HCT for WAS have indicated that although HLA-matched sibling donors have the
best outcomes (81% to 88%), when such a donor is not available, a matched unrelated donor should be
considered (71% event free survival), although results are best in patients age\ 5 years. Whereas most
of the experience to date in Asia, Europe, and North America has been with myeloablative conditioning reg-
imens, more recently, reduced-intensity conditioning (RIC) regimens also have been used with success. The
issue of whether mixed chimerism post-HCT (which has a higher incidence in RIC transplantation) is asso-
ciated with increased autoimmune manifestations in patients with WAS remains to be resolved.
Biol Blood Marrow Transplant 15: 84-90 (2009)  2009 American Society for Blood and Marrow TransplantationKEY WORDS: Wiskott-Aldrich syndrome,Wiskott-Aldrich syndrome protein, X-linked thrombocytopenia,
Hematopoietic stem cell transplantation, Reduced-intensity conditioning regimenINTRODUCTION
In 1937, Alfred Wiskott, a German pediatrician,
described 3 brothers who presented with thrombocy-
topenia, bloody diarrhea, eczema, and recurrent ear
infections and died at young ages from intestinal
bleeding and sepsis. Wiskott associated the hemor-
rhagic diathesis with platelet dysfunction. The obser-
vation that all 3 brothers were affected but their 4
sisters exhibited no symptoms led Wiskott to propose
that the syndrome is due to a hereditary thrombopa-
thia [1]. In 1954, Aldrich et al. [2] reported that in 61Department of Pediatrics, University ofWashington, Se-
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6/j.bbmt.2008.10.007generations of a family, 16 of 40 males, but no females,
died of a disease similar to that described by Wiskott,
thus suggesting an X-linked mode of inheritance.
Today, Wiskott-Aldrich syndrome (WAS) is defined
as an X-linked hereditary disorder associated with
combined immunodeficiency, thrombocytopenia,
small platelets, eczema, and an increased risk of auto-
immune disorders and cancers.WAS has a broad range
of clinical phenotypes [3,4]. In this article, we discuss
WAS protein (WASP) function, clinical and patholog-
ical manifestations associated with mutations of the
WASP gene, and the current state-of-the-art treatment
and outcomes in patients with WAS.WASP: FUNCTIONS, MUTATIONS, AND
RESULTING PHENOTYPES
WAS is a rare X-linked immunodeficiency disor-
der with a variable clinical phenotype that correlates
with the type of mutation in the WASP gene. WASP
is a key regulator of actin polymerization in hemato-
poietic cells that has well-defined domains involved
in signaling, cell locomotion, and immune synapse
formation. WASP consists of 12 exons, encodes
a 502-amino acid protein that is expressed selectively
in hematopoietic cell–derived lineages, and contains
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properties. ClassicWAS, as well as X-linked thrombo-
cytopenia (XLT) and intermittent XLT [5], are char-
acterized by chronic microthrombocytopenia, caused
by mutations in the WASP gene [6]. A third clinical
phenotype, congenital X-linked neutropenia, has
been found in males with missense mutations in the
Cdc42-binding domain of WASP [7,8].CLINICAL AND PATHOLOGICAL
MANIFESTATIONS
Incidence and Clinical Phenotypes
The estimated incidence of symptomatic individ-
uals with WASP genemutations is approximately 1 in
100,000. Clinical manifestations suggesting WAS/
XLT often are present at birth and include petechiae,
bruises, and bloody diarrhea. Excessive hemorrhage
after circumcision is an early diagnostic clue, as is ec-
zema in infancy and childhood. The most consistent
finding at diagnosis of both classic WAS and XLT is
thrombocytopenia and small platelet size. Infections,
including otitis media with drainage of mucoid mate-
rial, bacterial pneumonia, and skin infections, are
frequent complaints. Patients with XLT have less
problems with eczema and infections and often are
misdiagnosed with idiopathic thrombocytopenia. Pa-
tients with X-linked neutropenia are affected at birth,
but their symptoms do not resemble those of classic
WAS or XLT. A simple scoring system based on clin-
ical symptoms has been developed to differentiate
these distinct clinical phenotypes caused by WASP
mutations (Table 1) [3].
Defects of the Immune System
Both T and B lymphocyte functions are affected in
WAS. In classic WAS, the absolute number of
lymphocytes often decreases over time, resulting in
lymphopenia of variable severity. IgG and IgM areTable 1. Scoring System to Define Clinical Phenotypes Associated
IXLT
Score <1 1 2
Thrombocytopenia -/+ + +
Small platelets + + +
Eczema - - (+
Immunodeficiency - -/(+) (+
Infections - - (+
Autoimmunity and/or malignancy - - -
Congenital neutropenia - - -
IXLT, intermittent XLT.
Scoring system: -/(+), absent or mild; -/+, intermittent thrombocytopenia; (+),
quelae; +, thrombocytopenia, persistent but therapy-responsive eczema, and r
eczema that is difficult to control and severe, life-threatening infections. Becau
(albeit at a lower rate than those with classic WAS), a progression from a score
Winkelstein lA, eds. Immunologic Disorders in Infants and Children. Fifth edition.generally within the normal range, whereas IgA and
IgE are elevated. Antibody responses may be adequate
to some antigens and insufficient to others, including
abnormal antibody responses to polysaccharide anti-
gens and to bacteriophage FX174 [9]. In contrast,
most patients with XLT exhibit a robust response to
bacteriophage FX174, often comparable to that seen
in healthy control subjects [3]. Abnormal T cell func-
tion is suggested by diminished, but not absent, prolif-
erative responses to mitogens and allogeneic cells and
lack of response to immobilized anti-CD3monoclonal
antibody [3]. An increased incidence of Pneumocystis
jiroveci pneumonia in patients with classic WAS points
to a significant T cell defect. More recent studies
suggest that B cell function is equally affected
[10,11]. Absence of or truncated WASP also affects
innate immunity, including natural killer (NK) cell
function and the coexpression of WASP and F-actin
in the immunologic synapse [12]. The involvement
of the actin cytoskeleton in cell migration and cell traf-
ficking of myeloid cells, macrophages, dendritic cells,
and Langerhans cells makes these lineages particularly
vulnerable toWASP mutations. Lack ofWASP causes
the inability to assemble podosomes in monocytes,
macrophages, and dendritic cells, resulting in severe
defects in adhesion and motility [13].
Platelet Abnormalities
The majority (84%) of patients with WAS/XLT
have a history of bleeding, including petechiae, epi-
staxis, hematemesis, and melena. Life-threatening
bleeding, including gastrointestinal and intracranial
hemorrhage- occurs in 30% of patients with WAS
[14]. Increased expression of phosphatidylserine on
the surface of circulating platelets has been interpreted
as an indication of increased phagocytosis and destruc-
tion of platelets in the spleen in WAS/XLT [15]. An
alternative explanation postulates decreased platelet
production resulting from ineffective thrombocyto-
poiesis [9].withWASP Mutations
XLT Classic WAS XLN
3 4 5 0
+ + + -
+ + + -
) + ++ (+)/+/++ -
) + + (+)/+ -
) + +/++ (+)/+/++ -
- - + -
- - - +
mild, transient eczema or mild, infrequent infections not resulting in se-
ecurrent infections requiring antibiotics and often IVIG prophylaxis; ++,
se patients with XLT may develop autoimmune disorders or lymphoma
of 1 or 2 to a score of 5 is possible for XLT. (From Stiehm ER, Ochs HD,
Philadelphia: Saunders; 2004. Used with permission.)
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Autoimmune hemolytic anemia is the most
common autoimmune manifestation of WAS/XLT,
followed by vasculitis, renal disease, Henoch-Scho¨n-
lein–like purpura, and inflammatory bowel disease
[14-16]. The incidence of autoimmune disease gener-
ally is lower XLT than in classic WAS. A high serum
IgM concentration has been linked to the development
of autoimmune disease.
Malignancies
Malignancies can occur during childhood, but are
more frequent in adolescents and young adults with
the classic WAS phenotype [14]. The most frequent
malignancies reported are B cell lymphoma (often
Epstein-Barr virus–positive) and leukemia. In one
study, only 1 of 21 patients who developed a malig-
nancy was alive more than 2 years after diagnosis
[14]. The incidence of malignancies in patients of the
XLT phenotype is increased, but is lower than that in
classic WAS.
Molecular Basis
Several functional domains based on the genomic
structure of WASP have been identified, including
the pleckstrine homology (PH) domain; a WASP
interactive protein (WIP) binding domain; a basic
region; a guanosine triphosphatase binding domain,
also called the Cdc42- or Rc-interactive binding motif;
a proline-rich region; and the N-terminal verproline
homology domain, cofilin homology domain, and
acidic (VCA) region [3]. The PH domain, located close
to the N-terminal region of WASP, is considered
important for the localization of proteins through
interaction with other proteins or lipids and may
play a role in the binding of cytoplasmic proteins to
membranes.
By associating withWIP,WASP is stabilized in the
inactive conformation. When phosphorylated, WIP
allows WASP to disengage from the WIP–WASP
complex, thus inducing WASP activation. WASP rec-
ognizes the guanosine-5’-triphosphate (GTP)-bound
form but not the guanosine 5’-diphosphate (GDP)-
bound form of Cdc42 [17] and binds to Cdc42-GTP
with a 500-fold greater affinity than to Cdc42-GDP
[18]. The process leads to actin polymerization and
stabilization of actin filaments. The Cdc42-binding
domain, located in exons 7 and 8 of the WASP gene,
regulates the formation of filopodia and controls cell
polarity and chemotaxis. The VCA domain plays
a key role in the regulation of actin polymerization.
When WASP is activated by Cdc42-GTP, the C-
terminal region of WASP binds to Arp2/3 and pro-
motes nucleation of actin filaments [19].
The SH3-binding domain, a proline-rich region in
exon 10, allows WASP to interact with the SH3domains of selected signaling molecules, including
the cytosolic adaptor proteins, Grb2, P47nck , Fyn,
Lck, c-Src, and P47phox. WASP also interacts with
the Tec family of cytoplasmic tyrosine kinases, Btk,
Tec, PLC-g1, and Itk. Consequently, WASP has key
functions in hematopoietic cell lineages participating
in intracellular signaling, cytoskeleton and actin poly-
merization, chemotaxis, phagocytosis, and cell–cell in-
teraction through synapse formation, which allows
contact between T and B cells and between cytotoxic
cells and their targets.SPECTRUM OF WASP MUTATIONS
Through the analysis of affected members from
270 unrelatedWAS families from 3 large referral areas
(United States, Italy, and Japan), a total of 158 unique
WASP gene mutations have been identified. The most
common are missense mutations, followed by splice-
site mutations, short deletions, and nonsense muta-
tions. Insertions, complex mutations, and large
deletions are less frequent. Most deletions and inser-
tions involve fewer than 10 nucleotides and resulte in
frame shifting and early termination of transcription.
Amino acid substitutions typically are located in exons
1-4. Splice-site mutations occur predominantly in the
downstream half of the WASP gene (introns 6-12).
Mutations affecting invariant splice sites may result
in multiple splicing products, which often include
small amounts of normal WASP cDNA. Six muta-
tional hotspots, defined as occurring in . 2.5% of
the population, have been identified. Three of these
hotspots represent point mutations within the coding
regions, whereas the other 3 involve splice sites [20].GENOTYPE–PHENOTYPE CORRELATION
Using the WAS/XLT/neutropenia scoring system
[3] to determine the clinical severity (Table 1), the
most consistent genotype/phenotype correlation was
observed when patients were divided into 2 categories:
WASP1, in which the mutated protein is expressed,
and WASP-, in which the protein is absent or trun-
cated. With few exceptions, Patients with mutations
that allow the expression of normal-sized mutated
protein, often in reduced quantities, have the XLT
phenotype. In contrast, patients with lymphocytes
not expressing WASP or expressing only truncated
WASP are more likely to have the classicWAS pheno-
type (P\ .001). Note that progression to a score of 5,
caused by either autoimmune disease or malignancy,
was observed in both groups, but was far more
frequent in the WASP- patients with an initial score
of 3 or 4. Exceptions did occur, however, making it dif-
ficult to accurately predict the clinical course in indi-
vidual cases based solely on the type of WASP
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observed in some patients with WAS do not seem to
influence the clinical phenotype, although they do pro-
vide important information on the role ofWASP in the
survival of lymphocyte subsets [21].DIAGNOSIS OF WAS/XLT
Because of the wide spectrum of clinical findings,
the diagnosis of WAS/XLT should be considered in
any male patient presenting with petechiae, bruises,
and congenital or early-onset thrombocytopenia
associated with small platelet size. The presence of
mild or severe eczema supports the diagnosis. Infec-
tions or immunologic abnormalities may be absent,
mild, or severe; autoimmune diseases develop more of-
ten in patients with WAS than in those with XLT.
Screening for WASP mutations can be performed by
flow cytometry using a suitable anti-WASP antibody;
this might miss patients with expression of mutated
WASP, however. Sequence analysis of the WASP
gene is essential to establishing a final diagnosis.
A combination of these 2 methods may aid in estimat-
ing the severity of the disease, although with caution.TREATMENTOF WAS/XLT
Reported median survival in patients with WAS is
age 20 years [14]. Death results from infections, bleed-
ing complications, autoimmune diseases, and malig-
nancies. Short of hematopoietic cell transplantation
(HCT), there currently is no curative therapy for
WAS, although gene therapy is under study. Conven-
tional treatment and supportive care include use of
prophylactic antibiotics, such as trimethoprim-
sulfamethoxazole, to prevent Pneumocystis jiroveci
pneumonia; use of acyclovir to prevent herpes simplex
infection; and judicious use of platelet transfusions to
treat major bleeding episodes, such as acute central
nervous system hemorrhages or gastrointestinal bleed-
ing, or to prevent excessive blood loss during surgery.
Blood products should be irradiated and tested for cy-
tomegalovirus. Intravenous immunoglobulin (IVIG)
therapy is indicated in patients with a significant anti-
body deficiency. Immunosuppressive treatment, at
least intermittently, may be required if autoimmune
manifestations are present. Autoimmune cytopenia of-
ten responds to a monoclonal antibody targeting the
CD20 antigen (rituximab), which might be a relatively
acceptable therapy for those patients already being
treated with IVIG. The use of elective splenectomy
has been advocated in selected patients with WAS/
XLT, to reverse the thrombocytopenia and arrest the
bleeding tendency by increasing the number of circu-
lating platelets. But splenectomy markedly increases
the risk of septicemia in these and is not routinelyrecommended; patients who do undergo splenectomy
require life-long antibiotic prophylaxis. Splenectomy
also is not desirable in a child who might undergo
HCT in the future, due to the significant risk of late
death from overwhelming sepsis despite the prophy-
lactic antibiotic use in these patients.TRANSPLANTATION FORWAS
Before 1990, the use of HCT to treatWAS was re-
stricted to patients with matched sibling donors and
mainly to those who had already developed life-threat-
ening complications of the disease. The first sibling
donor marrow transplantation for WAS was reported
in 1968 [22]. The recipient initially recovered only do-
nor-derivedT cell immunity and required retransplan-
tation with myeloablative conditioning secondary to
clinically significant thrombocytopenia [23], and then
died at age 36 secondary to complications of acute
and chronic graft-versus-host disease (GVHD). But
since that first transplantation, HCT from a matched
sibling donor has become the standard of care. More
recently, after reports of successful HCTs using
closely matched unrelated donors, many more boys
and young men with these conditions are being treated
with HCT at younger ages.
Because correction of all aspects of WAS requires
myeloid and lymphoid engraftment, to date, the vast
majority of patients undergoing HCT for WAS have
been conditioned with myeloablative protocols con-
sisting of busulfan, cyclophosphamide, and antithymo-
cyte globulin. Despite this, however, a small fraction
(10%) of patients reject their first transplantation
(although retransplantation is successful in most),
and a substantial proportion (an estimated 30%) are
long-term mixed chimeras. Older patients with more
comorbidities who undergo HCT using unrelated do-
nor sources have poorer survival post-HCT than
younger, healthier patients.
A study from the Center for International Blood
and Marrow Transplant Research (CIBMTR) pub-
lished in 2001 reflects contemporary results with mye-
loablative preparative regimens in HCT for WAS.
That analysis reviewed the outcomes of 170 allogeneic
HCTs performed worldwide between 1980 and 1996,
with an emphasis on examining the impact of donor
type (matched related vs unrelated donor) on survival
[24]. The overall survival 5 years post-HCT was
87% in the recipients of matched sibling transplants
and 71% years in the recipients of matched unrelated
donor transplants in patients age\ 5 years. A poorer
outcome was reported for older recipients (. 5 years
at time of HCT) of matched unrelated donors. The
survival rate was only 52% in recipients of transplants
from other related donors (haploidentical familymem-
bers). Of note, patients age\ 5 years at the time of
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either matched sibling or closely matched unrelated
donor grafts. This trend toward comparable survival
in children undergoing HCTwith sibling versus unre-
lated donors for various disorders is now well recog-
nized and holds particularly for transplantations
performed at centers with considerable experience in
the use of unrelated marrow and cord blood grafts.
But despite similar long-term survival, transplanta-
tion-related complications were more frequent and
more severe in patients receiving matched unrelated
donor grafts; 56% of recipients of unrelated grafts
experienced acute GVHD (aGVHD), compared with
only 16 % of recipients of matched sibling donor
grafts. The physician-reported clinical and perfor-
mance status (Lansky score) at last follow-up for
each patient indicated that most survivors of matched
sibling and matched unrelated HCT had been ‘‘cured’’
or had significantly ‘‘improved quality of life’’ after the
procedure. Poorer results were reported after mis-
matched (eg, haploidentical family member) HCT.
This retrospective registry-based analysis was not
able to examine details of the graft status (eg, long-
term chimerism), impact of previous splenectomy,
post-HCT platelet counts, persistent or new clinical
complications, or any patient- or family-generated as-
sessment of quality of life. Nonetheless, it convinced
most transplantation centers that HCT should be pur-
sued for this diagnosis, and that HCT at a young age
confers a survival advantage.
A more current (unpublished) analysis from the
CIBMTR comparing 113 recipients of unrelated
bone marrow versus 65 recipients of unrelated cord
blood transplants between 1995 and 2005 has demon-
strated equivalent survival 3 years posttransplantation
for recipients age\ 5 years at the time of the proce-
dure (73% vs 75%).
Outcomes of unrelated donor HCT for WAS at
Cincinnati Children’s Hospital Medical Center
(CCHMC) (A. Filipovich, personal communication)
are consistent with the notion that a center’s experi-
ence with treatment of a rare disease, as well as the
availability of supportive care measures (such as rapid
preemptive diagnosis of infectious disease by polymer-
ase chain reaction and increased numbers of microbi-
cidal agents) can improve outcomes. At CCHMC, 33
boys have been treated for WAS since 2000. All 21 of
the boys treated before age 5 years (19 using unrelated
donor grafts) are alive and hematologically reconsti-
tuted; however, during the first year after HCT,
approximately half of the boys experienced some
degree of aGVHD and/or immune cytopenia. These
complications have since resolved.
In Europe, since 1968, data on patients undergoing
HCT for primary immunodeficiencies have been col-
lected in a central SCETIDE registry established for
the European Society for Immunodeficiency and theEuropean Group for Blood and Marrow Transplanta-
tion (EBMT). Between 1968 and 2000, 103 patients
undergoing HCT for WAS (with a minimum follow-
up of 6 months) were reported to the registry from
37 centers in 18 countries [25]. Thirty-three patients
received grafts from an HLA-matched sibling donor;
5, from another HLA-matched related donor; 45,
from a mismatched related donor; and 20, from
a matched unrelated donor (Some of these patients
also were included in the CIBMTR database.)
The 3-year overall survival for the entire group was
62%. That for matched sibling donor HCT was
81%, significantly higher than that for mismatched re-
lated donorHCT (45%) (P\ .001). Because of the rel-
atively small number of patients, survival in patients
undergoing unrelated donor HCT (75% of whom
were fully HLA-matched) were analyzed together
with those of patients with other non–severe combined
immunodeficiencies and was found to not differ signif-
icantly from that in matched sibling donor HCT (59%
vs 71%).
A more recent study from European centers exam-
ined the long-term outcome of 96 WAS patients who
underwent HCT between 1979 and 2001 after receiv-
ing a myeloablative conditioning regimen and who
survived at least 2 years posttransplantation [26].
Transplantations were performed at 19 centers in 14
European countries. In the same time period, 49 other
WAS patients underwent HCT in these centers but
died within the first 2 years posttransplantation. Of
the 96 patients who were alive 2 years after HCT, 93
were still alive at the time of the study, with a median
follow-up of 7 years (range, 2 to 25 years), for an over-
all long-term survival of 64% (93/145). Events in-
cluded in the analysis of the 96 patients included
chronic GVHD (cGVHD), autoimmunity, infections,
and sequelae before or after HCT. Overall, the 7-year
event-free survival was 75%; event-free survival was
significantly influenced by donor group, being 88%
in matched sibling donor HCT, 71% in matched un-
related donorHCT (P5 .03), and 55% inmismatched
related donor HCT (P5 .003). In 20% of the patients,
cGVHD-independent autoimmunity was strongly
associated with mixed or split (donor T cell, host
myeloid and B cell) chimerism status, suggesting that
residual host cells can induce autoimmune disease
despite the coexistence of donor cells. The overall in-
cidence of autoimmunity was 8% in the patients with
full donor chimerism and 71% in those with mixed/
split chimerism (P 5 .001). Autoimmune manifesta-
tions were more frequent in unrelated donor HCT
(28%) and mismatched related donor HCT (26%)
than in matched sibling donor HSCT (11%). A more
detailed analysis of chimerism performed on different
cell lineages based primarily on WASP expression
should provide further insight into which host cell lin-
eages could provoke autoimmunity. Further follow-up
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versus mixed chimeras.
Infectious complications related to splenectomy
were also a significant finding in the study, suggesting
that splenectomy should be avoided in patients
with WAS who are candidates for HCT or who have
already been treated with HCT.
The Spanish Working Party reported a successful
outcome in 8 of 10 patients with WAS undergoing
HCT with HLA-matched grafts (3 matched sibling
and 7 unrelated donors) [27]. Of note, 2 of 10 patients
who were mixed chimeras post-HCT died, 1 of
lymphoproliferative disease after undergoing a second
HCT for late graft failure and 1 from grade IV
aGVHD. The remaining 8 patients with full donor
chimerism remain alive, with a median follow-up of
101 months.
The latest unpublished figures from the SCE-
TIDE database (presented at EBMT 2008) revealed
an overall survival of 71% survival in 166 children
withWASwho underwentHCT at 37 centers between
1968 and 2005 (A.Gennery, personal communication).
Investigators at Great Ormond Street Hospital
have explored the use of reduced-intensity condition-
ing (RIC) HCT in children with primary immunode-
ficiencies [28]. More than 150 children with primary
immunodeficiencies have undergone RIC HCT be-
tween 1998 and 2008. A survival advantage was seen
for the use of RIC unrelated donor HCT in non–
severe combined immunodeficiencies, particularly T
cell immunodeficiencies [29]. However, there was an
increased incidence of mixed chimerism after RIC
compared with myeloablative HCT particularly with
matched related donors [30]. In patients with WAS,
mixed chimerism appeared to have a detrimental effect
on event-free survival after HCT, due to an increased
incidence of autoimmunity.
Between 1995-2007 at Great Ormond Street Hos-
pital, a total of 17 patients with WAS (median age, 27
months) underwent matched sibling donor (n 5 5) or
unrelated donor (n 5 12) HCT (P. Veys, personal
communication). Myeloablative conditioning (busul-
phan/cyclophosphamide) was used in 5 patients, mod-
ified myeloablative conditioning (MMC; treosulphan/
fludarabine) [31] was used in 6 patients, and RIC
(fludarabine/melphalan) was used in 6 patients. All pa-
tients survived, with a median follow-up of 4 years.
Four of the 17 patients had split chimerism, all after
unrelated donor HCT: 2 of 6 after RIC, 1 of 5 after
MAC, and 1 of 6 afterMMC. All 4 of these patients un-
derwent in vivo T cell depletion with alemtuzumab,
1mg/kg total dose on days -8 to -4. Subsequently, 3 pa-
tients underwent unrelated donor HCT with MMC
with reduced alemtuzumab, 0.6 mg/kg total dose on
days -8 to -6, and all achieved 100% donor chimerism,
with only 1 patient experiencing grade 2 aGVHDof the
skin. Of interest, 3 of 4 patients with mixed chimerismdeveloped aGVHD . grade 2, as opposed to 3 of 15
with full donor chimerism (P\ .05). RIC or MMC
protocols may still be applicable for WAS patients,
but some graft-versus-marrow reaction is required to
secure 100% donor chimerism.
In summary, in the current era, several factors ap-
pear to influence the ultimate success of HCT for
WAS. These include the patient’s age at transplanta-
tion and general health status. Young age is associated
with fewer comorbidities and less frequent pretrans-
plantation exposure to herpesviruses and enteric vi-
ruses. Donor selection should take into consideration
high-resolution tissue typing, younger age, and spe-
cific viral immunity. The careful selection of pretrans-
plantation conditioning is critical to increase the
likelihood of durable and complete engraftment of do-
nor-derived lymphohematopoietic cells. A myeloabla-
tive conditioning regimen is the standard of care for
WAS patients and has demonstrated very good results
in both related and unrelated matched donor HCT in
younger patients. RIC can significantly reduce early
transplantation-related morbidity and mortality, espe-
cially in older children and adolescents, who may have
more comorbidities pretransplantation. These patients
are at greater risk for mixed chimerism, associated com-
plications, and delayed graft failure, however. Further
evaluation and follow-up of patients receiving RIC is
needed.
HCT is indicated in all patients with classic WAS
and in those with XLT who have a sibling donor. In
patients with XLT lacking a histocompatible sibling
donor, unrelated donor HCT from a 6/6 antigen-
matched cord or 8/8 allele-matched marrow remains
controversial, requiring assessment of the risk of trans-
plantation-related morbidity and mortality against the
likelihood of a cure. Because HCT is the accepted
treatment of choice for patients with classic WAS,
careful evaluation of long-term benefits and complica-
tions is essential, with documentation of the complete-
ness of late donor-derived chimerism, immunologic
correction, and measures of medical, psychological,
and social well being.ACKNOWLEDGMENTS
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